ES2058898T3 - Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus. - Google Patents

Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus.

Info

Publication number
ES2058898T3
ES2058898T3 ES90904636T ES90904636T ES2058898T3 ES 2058898 T3 ES2058898 T3 ES 2058898T3 ES 90904636 T ES90904636 T ES 90904636T ES 90904636 T ES90904636 T ES 90904636T ES 2058898 T3 ES2058898 T3 ES 2058898T3
Authority
ES
Spain
Prior art keywords
papilomaviruses
preventive
useful
tumors induced
pharmaceutical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904636T
Other languages
English (en)
Inventor
Guerrino Meneguzzi
Richard Lathe
Marie-Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of ES2058898T3 publication Critical patent/ES2058898T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION, EN UNA COMPOSICION FARMACEUTICA DESTINADA A LA PREVENCION Y AL TRATAMIENTO DE LOS TUMORES INDUCIDOS POR LOS PAPILOMAVIRUS, EN PARTICULAR EL VIRUS HPV-16, DE UN POXVIRUS RECOMBINANTE QUE COMPRENDE UNA SECUENCIA DE ADN HETEROLOGO QUE CODIFICA AL MENOS PARA LA REGION ESENCIAL DE UNA PROTEINA NO ESTRUCTURAL DE UN PAPILOMAVIRUS ASI COMO LOS ELEMENTOS DE REGULACION QUE ASEGURAN SU EXPRESION EN LAS CELULAS SUPERIORES. MAS EN PARTICULAR, SE TRATA DE LAS PROTEINAS E5, E6, E7 DEL VIRUS HPV-16.
ES90904636T 1989-03-06 1990-03-06 Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus. Expired - Lifetime ES2058898T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8902897A FR2643817B1 (fr) 1989-03-06 1989-03-06 Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus

Publications (1)

Publication Number Publication Date
ES2058898T3 true ES2058898T3 (es) 1994-11-01

Family

ID=9379397

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90904636T Expired - Lifetime ES2058898T3 (es) 1989-03-06 1990-03-06 Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus.

Country Status (9)

Country Link
EP (1) EP0462187B1 (es)
JP (1) JP2926270B2 (es)
AT (1) ATE91630T1 (es)
CA (1) CA2050304C (es)
DE (1) DE69002325T2 (es)
DK (1) DK0462187T3 (es)
ES (1) ES2058898T3 (es)
FR (1) FR2643817B1 (es)
WO (1) WO1990010459A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
US20090028874A1 (en) * 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
CN101617052A (zh) 2007-01-30 2009-12-30 特兰斯吉恩股份有限公司 用于免疫的乳头瘤病毒e2多肽
ES2536747T3 (es) 2009-01-20 2015-05-28 Transgene Sa ICAM 1 soluble como biomarcador para predicción de respuesta terapéutica
NZ595290A (en) 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
RU2555340C2 (ru) 2009-04-17 2015-07-10 Трансжене Са Биомаркер для мониторинга пациентов
BRPI1007744A2 (pt) 2009-05-12 2017-06-27 Transgene Sa método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas
JP5650212B2 (ja) 2009-07-10 2015-01-07 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者を選択するためのバイオマーカーおよび関連方法
AU2010275764A1 (en) 2009-07-21 2012-03-15 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
CN107206063B (zh) 2014-12-01 2021-09-28 特兰斯吉恩股份有限公司 稳定的液体痘苗病毒制剂
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US20210187100A1 (en) 2018-09-06 2021-06-24 Bavarian Nordic A/S Storage Improved Poxvirus Compositions
KR20220153587A (ko) 2020-03-12 2022-11-18 버베리안 노딕 에이/에스 폭스바이러스 안정성을 개선하는 조성물

Also Published As

Publication number Publication date
WO1990010459A1 (fr) 1990-09-20
CA2050304A1 (fr) 1990-09-07
ATE91630T1 (de) 1993-08-15
DE69002325D1 (de) 1993-08-26
CA2050304C (fr) 2002-01-22
EP0462187B1 (fr) 1993-07-21
DE69002325T2 (de) 1993-12-02
JPH05503282A (ja) 1993-06-03
FR2643817A1 (fr) 1990-09-07
DK0462187T3 (da) 1993-10-18
FR2643817B1 (fr) 1993-12-17
EP0462187A1 (fr) 1991-12-27
JP2926270B2 (ja) 1999-07-28

Similar Documents

Publication Publication Date Title
ES2058898T3 (es) Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus.
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
CL2009000648A1 (es) Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02).
ES2120274T3 (es) Utilizacion de un extracto de una bacteria filamentosa no fotosintetica y composicion.
MY138860A (en) Hiv protease inhibitors.
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
EA199900553A1 (ru) Чрескожная терапевтическая система
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
ES2163795T3 (es) Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
ATE289293T1 (de) Substituierte aminoalkylamid-derivate als antagonisten des follikel-stimulierenden hormons
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
BRPI0418157A (pt) terapêutica de tumores alogênicos
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
FI801228A (fi) 6-substituerade 11-alkylen-morfantridiner foerfaranden foer deras framstaellning och terapeutiska medel innehaollande dessa
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
HK1117035A1 (en) Methods of applying ionization radiation for therapy of hiv infection

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 462187

Country of ref document: ES